Neurobiological Evidence in Alcohol Addiction Can Help Pharmacological Treatment Personalization
Received: 03-Nov-2015 / Accepted Date: 05-Nov-2015 / Published Date: 15-Nov-2015 DOI: 10.4172/2472-095X.1000e103
16215Introduction
Addiction is a burden disease that affects a wide part of the world population and is the most harmful form of abuse for users and for society [1]. Nevertheless pharmacological treatment for alcohol use disorders (AUD) have a modest efficacy and none of the molecules accepted in North America and Europe (Disulfiram, Naltrexone, Acamprosate, Sodium Oxibate, Nalmefene) can be considered a gold standard for the treatment of alcohol use disorders [2-7].
On the light of this consideration many researchers are underlying the importance of personalization in pharmacotherapy by matching patient features with drug hallmark as a strategy to improve the efficacy of the treatment [3,6]. In the perspective of personalizing treatments, the chance to include our neurobiological knowledge, though challenging, can’t be overlooked.
Indeed, in the last years, thanks to neuroimaging non-invasive techniques, we had the chance to explore the central nervous system involved with the genesis of addiction and speculate on new interpretative models [8]. In particular the scientists agree on the presence of two complementary pathological neurobiological alterations: on one hand the improvement of positive reinforcement and negative reinforcement as drive mechanisms toward the use of drugs of abuse, and on the other hand the lack of control ability due to cognitive prefrontal control deficit and changes in thalamic-cortex circuitry of habit [9].
This article tries to match clinical features corresponding to specific neurobiological pathological addiction and pharmacotherapy of alcohol use disorders as a new frontier of personalization of treatment.
Personalization of pharmacological treatment
Between the few alcoholism pharmacological treatment guidelines, the most renowned are NICE (National Institute of Clinical Excellence) Guidelines [10] that identify Naltrexone and Acamprosate as the first treatment line due to the presence of a high level of efficacy. Recent international reviews adopt the same position [5,11] but there are also other points of view that highlight the value of Sodium Oxibate and Disulfiram for the treatment of AUD [6,12,13].
In particular Skinner review article concluded indicating the blind studies with placebo as an incorrect methodology to research Disulfiram efficacy and, based on results with open-label studies, pointed out that Disulfiram is a safe and efficacious treatment compared to other pharmacological treatments for AUD [13]. The Leone et Al Cochrane Review establishes that Sodium Oxibate is better than Naltrexone and Disulfiram in maintaining abstinence and these side effects are not statistically different from those with BZD, NTX or Disulfiram [14]. Moreover Caputo et Al, analyzing 20 year of Italian physician experience with Sodium Oxibate treatment clarifies that the drug is safe if it is used at therapeutically dosage and under medical supervision [15]. On the light of these considerations there aren’t efficacy based criteria or side effects based criteria for choosing between the four abovementioned molecules, that have got the same treatment indication (maintaining abstinence from alcohol or preventing relapse) but widely different mode of action. Personalization of treatment is therefore suggested by many authors as the correct approach to alcoholism pharmacological treatment [3,6,16].
On the light of this consideration neurobiology of addiction and in particular of alcohol dependence can give us a key to differentiate the clinical use of these four drugs and can be added to other matching variables for treatment personalization as psychiatric and internal comorbidity and typology of alcoholism and craving.
Neurobiological Evidence
Behavioural control is not only a cognitive function but depends on the dynamic and interconnected relations between reward impulsive system and control inhibitory system [17]. The first involves basal ganglia and limbic system and sustain hedonic state, gratification and motivations to act, the second involves prefrontal cortex and corticostriatal connections and sustain regulation of drives, anticipation of adaptive behavioural strategies, integration of drives to act and personal goals [18].
Chronic alcohol abuse causes critical changes in neural reward and motivational systems, and simultaneously induces deficits in inhibitory control [19]. These neurobiological adaptations are thought to account for compulsive alcohol use despite negative consequences and for the emergence of negative emotional state when the alcohol blood level decreases [9].
Th e progression of alcohol dependence consists in a worsening dysfunction of the interconnected reward and control circuits, which becomes increasingly imbalanced [19].
Drive System Disregulation
Positive reinforcement
This theory focuses on enhancement of dopaminergic mesolimbiccortical circuitry of gratification by alcohol repeated consumption. In particular there is an increased dopamine transmission in the nucleus accumbens and associated ventral striatal areas [20] that initially mediates the gratification effect of drug and subsequently is able to increase salience and appetitive value of substance related stimuli [21]. This mechanism is called positive reinforcement of the drug. Alcohol related positive reinforcement is mediated by GABAA receptor activation that induces a disinhibition of GABAergic neurons in the VTA and subsequently a disinhibition of dopaminergic neurons that project from the VTA to the NAcc [22]. Moreover alcohol promotes the release of endogenous opioid peptides within the mesolimbic dopamine circuitry [23] causing the disinhibition of dopamine release to the NAcc [24].
According with this theory the patient will look forward using alcohol to exert its hedonic effects with increased motivation and gratification due to positive reinforcement. In this case the pharmacotherapies that we can speculate to be more sensible to the neurobiological mechanism are two, depending on patient goal:
- if the patient goal is total abstinence: Sodium Oxibate, that exert an alcohol mimic effect acting on GABAB receptor and GHB receptor that result in a disinhibition of dopaminergic neurons in ventral tegmental area neurobiologically [25].
- if the patient goal is consumption control: Naltrexone or Nalmefene that antagonizes opioid specific effect decreasing the rewarding effects of alcohol [26] and reduces alcohol and alcohol cues stimulated dopamine output in striatum [27] accounting for a reduction in positive reinforcement power.
Negative reinforcement
Chronic alcohol consumption is associated with several neuroadaptations: decreased activity of the mesocorticolimbic dopamine system determinated by increases in reward thresholds [28], sensibilization of dynorfine system [29] increased deregulation of brain stress system [30], decreases GABAreceptor function [31] and development of hyperglutamatergic state [32] The clinical correlation of this neurobiologic adaptation is chronic irritability, hyperkatifeia, malaise, dysphoria, alexithymia, loss of motivation for natural rewards [33] and increasing motivation for alcohol intake: this pathological mechanism is called negative reinforcement.
According to this theory, chronic alcohol consumption causes an alteration of the homeostasis of the reward/stress system by decreasing the reward threshold on one hand and increasing the responsiveness of stress system and anti-reward molecules on the other hand. This would determine the research of alcohol to rebalance the system. In this case the pharmacotherapies that we can speculate to be the more sensible to the neurobiological mechanism are:
- Acamprosate that prevents the increase in glutamate in the nucleus accumbens [34] and the escalation in the hyperglutamatergic state [35].
- Sodium Oxibate that restore homeostasis both potentiating dopaminergic hedonic activity (as described below) and trough the conversion of Sodium Oxibate in GABA that activate GABAA and GABAB receptors obtaining ansiolytic and sedative effects [25].
- Novel molecules not yet approved that involve stress system (neuopeptide Y and CBR antagonist) [36].
Inhibitory System Disruption
In advanced phase of addiction, the disruption of orbitofrontal cortex, a brain region implicated in salience attribution and motivation, results in compulsivity and the disruption of cingulate gyrus, a brain region implicated in inhibitory control and conflict resolution, results in impulsivity [37].
Moreover, the gradual engagement of dorsal striatal, in the place of ventral striatum, in response to alcohol related stimuli, is the neurobiological base of habitual compulsive alcohol use [38].
Chronic alcohol consumers show frontal brain regions biases that impact on reward circuitry [19] and worsen inhibitory control tasks [39] due to neurobiological degeneration, possibly linked to neuroinflammatory sequelae of alcohol-related chronic microglial activation [40], in the anterior cingulate cortex, dorsolateral prefrontal cortex, and orbitofrontal cortex [41,42].
According with this theory drug seeking habit, elicited by drug associated stimuli or emotional cues (both associated to drug reward through pavlovian conditioning), is divorced by patient goals and can rise automatically (not depending on conscious awareness) and in contrast with major cognitive intentions [38].
In this case, premising that the clinical severity of the disease is often high and a residential treatment could be needed, the pharmacotherapy that we can speculate to be more sensible to the neurobiological mechanism is:
-Disulfiram: due to habit neurocircuitry enhancement and cortical deficits, the behavioural control ability is greatly compromised and the aversive effect of Disulfiram can play a role in enhancing it [43,44]. In particular the patient can assume the medication in a specific moment of the day that can be free from alcohol related stimuli or emotional cues and gain a control improvement for the rest of the day. Moreover the good clinical practice expect that Disulfiram should be administrated by a care giver that can help the patient to fill the gap of cortical deficit by daily brief medical management: from this perspective Disulfiram and care givers assume the role of extended mind [45] that supply neurodegenration.
Combination Treatment
Since neuroadaptations often coexist in a single patient, we can find contemporary enhancement of drive system (trough positive and/or negative reinforcement) and a lack of inhibitory ability. Thus it is rational to associate pharmacological treatment, in particular the association between Disulfiram and Sodium Oxibate [46], Disulfiram and Naltrexone [47] and Disulfiram and Acamprosate [48] have already been studied demonstrating their safety and efficacy [6,49].
Conclusion
Neurobiology is an important key to develop pharmacological treatment for alcohol dependence, especially focusing on the neurocircuitry target of pharmacotherapy. Since there is a strict connection, from a theoretical point of view, among neurobiological adaptations in both reward and control systems, and behavioural manifestation of addiction, this article has explored a possible rational match between medication and patient, based on the consistency between drug mechanism of action and patient behavioural manifestation derived from neurobiological adaptation. This scientific speculation needs experimental research to be validated. In the meanwhile, considering the absence of guidelines for pharmacological treatment personalization in AUD, this rational match could be taken in consideration for a good clinical practice.
References
- Cibin M, Caputo F, Addolorato G, Bernardi M (2013) Il Gamma idrossibutirrato (GHB) nellaricerca e nellapraticaclinica: efficacia e potenzialit脙聽d芒鈧劉abusoMission 38: 40-46.
- Koob GF (2010)The potential of neuroscience to inform treatment. Alcohol research and health 33: 144-151.
Citation: Vignoli T, Martino E, Caputo F (2015) Neurobiological Evidence in Alcohol Addiction Can Help Pharmacological Treatment Personalization. J Neuropsychopharmacol Mental Health 1: e103. DOI: 10.4172/2472-095X.1000e103
Copyright: © 2015 Vignoli T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
天美传媒 Access Journals
Article Tools
Article Usage
- Total views: 12048
- [From(publication date): 1-2016 - Jan 26, 2025]
- Breakdown by view type
- HTML page views: 11216
- PDF downloads: 832
